For the Inventor, By the Inventor

Enter assignee name

Bellinzona, Switzerland

Humabs Biomed Sa

Calculating rank

USPTO Granted Patents = 38

% Expired Patents = 2.6

EPO Patents = 12

Forward Citations = 49

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Davide Corti (38 out of 51 patents)

Antonio Lanzavecchia (10 out of 65 patents)

Ebony Benjamin (8 out of 9 patents)

4. Nicole Kallewaard-LeLay (8 out of 19 patents)

5. Josephine Mary McAuliffe (8 out of 11 patents)

6. Leslie Wachter (8 out of 9 patents)

7. Qing Zhu (8 out of 16 patents)

8. Andy Q Yuan (8 out of 14 patents)

9. Anna DeMarco (6 out of 6 patents)

10. Bret Sellman (4 out of 16 patents)

11. Frances Palmer-Hill (4 out of 6 patents)

12. Barbara Guarino (4 out of 4 patents)

13. Martina Beltramello (4 out of 6 patents)

14. Elisabetta Cameroni (4 out of 6 patents)

15. Christine Tkaczyk (4 out of 12 patents)

Core Competencies:

Neutralizing Antibodies

Influenza A

Influenza B

Hepatitis B Virus

RSV

Zika Virus

Rabies Virus

Ebola Virus

Clumping Factor A

Multispecific Antibodies

Passive Immune Responses

Active Immune Responses

38 patents: Sort by Forward Citations

1. 12492240 - NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF (2025-12-09),

2. 12404318 - Combination HBV therapy (2025-09-02),

3. 12325740 - Neutralizing anti-influenza B antibodies and uses thereof (2025-06-10),

4. 12312397 - Anti-O2 antibodies and uses thereof (2025-05-27),

5. 12304946 - Antibodies that neutralize hepatitis B virus and uses thereof (2025-05-20),

6. 12297258 - Antibodies againstspecies (2025-05-13),

7. 12037381 - Antibodies that potently neutralize hepatitis B virus and uses thereof (2024-07-16),

8. 12018068 - Anti-O1 antibodies and uses thereof (2024-06-25),

9. 11970527 - Antibody directed againstclumping factor A (ClfA) (2024-04-30),

10. 11932682 - Neutralizing anti-influenza A antibodies and uses thereof (2024-03-19),

11. 11926658 - Multispecific antibodies specifically binding to Zika virus epitopes (2024-03-12),

12. 11912757 - Antibodies specifically binding to Zika virus epitopes and uses thereof (2024-02-27),

13. 11787853 - Neutralizing anti-influenza b antibodies and uses thereof (2023-10-17),

14. 11730813 - Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof (2023-08-22),

15. 11723977 - Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof (2023-08-15),

Company Overview

Humabs Biomed SA is a biotechnology company based in Bellinzona, Switzerland, specializing in the development of innovative therapeutic solutions. The company focuses on harnessing the power of human antibodies to create treatments for infectious diseases and other serious health conditions. With a strong emphasis on research and development, Humabs aims to advance the field of immunotherapy, leveraging cutting-edge technologies to address unmet medical needs and improve patient outcomes globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

38 Patents

#2 in Bellinzona

#362 in Switzerland

#17,870 in the World

Bellinzona, Switzerland

Humabs Biomed Sa

Forward Citations = 49

41 inventors:

Davide Corti (38 out of 51 patents)

Antonio Lanzavecchia (10 out of 65 patents)

Ebony Benjamin (8 out of 9 patents)

4. Nicole Kallewaard-LeLay (8 out of 19 patents)

5. Josephine Mary McAuliffe (8 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Humabs Biomed Sa. Retrieved from https://idiyas.com/company/humabs-biomed-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…